Viral Vectors & Vaccines
PROGRAM CHAIRS:
Otto-Wilhelm Merten, PhD
Généthon
Johannes C.M. van der Loo, PhD
The Children's Hospital of Philadelphia

Cellular Therapies
PROGRAM CHAIRS:
Kelvin G.M. Brockbank, PhD
Tissue Testing Technologies LLC
Sébastien Sart, PhD
Hydrodynamics Laboratory, École Polytechnique

Baculovirus Expression Technology
PROGRAM CHAIRS:
Penny L. Post, PhD
Protein Sciences Corporation
Monique M. van Oers, PhD
Wageningen University

SUNDAY • MARCH 6, 2016

3:00 pm – 6:00 pm	**Welcome Reception** **Plus Exhibit Setup at The Mead Center for American Theater (Arena Stage)**

MONDAY • MARCH 7, 2016

7:00 am – 8:00 am	**Registration and Breakfast in the Exhibit Area, plus Exhibit Setup**		
8:00 am – 8:30 am	**Meeting Overview in the Kreeger Theater**		
	Viral Vectors and Vaccines Rehearsal Hall View Speaker Abstracts & Bios	**Cellular Therapies** Classroom View Speaker Abstracts & Bios	**Baculovirus Expression Technology** Kreeger Theater View Speaker Abstracts & Bios
8:30 am – 9:15 am	**Otto-Wilhelm Merten, PhD** • Généthon *Towards Efficient Production of Viral Vectors at Scale; Example: Improvements in AAV Vector Production*	**Mark F. Witcher, PhD** • Integrated Project Services *Using a Patient Centered Risk-Benefit Structure to Develop Appropriate Manufacturing Practices (AMPs) for Cell Therapy Products*	**Dominic Esposito, PhD** • Frederick National Laboratory for Cancer Research — *Technology Development to Improve Recombinant Protein Production Using Baculovirus-Infected Insect Cells*
9:15 am – 10:00 am	**Eduard Ayuso, DVM, PhD** • Université de Nantes *Identification and Quantification of DNA Species in rAAV Stocks by High-Throughput Sequencing*	**David F. Stroncek, MD** • NIH Clinical Center *Improving the Production of CAR T Cells*	**Kendra Steele, PhD** • ParaTechs Corporation *Improved Recombinant Protein Production with Vankyrin-Enhanced Baculovirus Expression Technology*
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:00 am	**Wilson Wolf Manufacturing Corporation**	**TECHNOLOGY WORKSHOPS**	**The Intellectual Property Law Office of Verne A. Luckow, LLC**
11:00 am – 11:30 am	**ViroCyt, Inc.**		**Aldevron, LLC**
11:30 am – 12:00 noon	**Pall Life Sciences**		
12:00 noon – 1:30 pm	**Lunch in the Exhibit Area** (**Poster Session** from 1:00 pm – 1:30 pm)		
1:30 pm – 2:15 pm	**Samuel C. Wadsworth, PhD** • Dimension Therapeutics — *The AAV Gene Therapy Platform for Rare Liver Diseases*	**Norman A. Goldschmidt** • Genesis Engineers, Inc. — *Designing and Building a Cellular Therapy Manufacturing Facility on an Accelerated Timeline*	**Imre Berger, PhD** • The European Molecular Biology Laboratory — *Baculovirus Expression: Old Dog, New Tricks*
2:15 pm – 3:00 pm	**J. Fraser Wright, PhD** • Spark Therapeutics, Inc. *Developing AAV Vectors to Support Clinical Program Advancement*	**Robert N. Ben, PhD** • University of Ottawa *Overcoming Obstacles Associated with Cryopreservation and the Impact in Cellular Therapies*	**Steven Reid, PhD** • University of Queensland *Approaches to Improve Yields of Baculovirus Biopesticides and Recombinant Proteins Using Insect Cell Technology*
3:00 pm – 3:30 pm	**Afternoon Break in the Exhibit Area**		
3:30 pm – 4:15 pm	**Ana Sofia Coroadinha, PhD** • Instituto de Biologia Experimental e Tecnológica (iBET) — *Challenges in Virus Producer Cell Line Development and Engineering: Novel Enabling Technologies Providing Solutions to Old Problems*	**Kleyopha Prathipati** • Adaptimmune LLC *Commercial-Ready Manufacture of Genetically Engineered T Cells Using CD3/CD28 Beads*	**Yoshifumi Hashimoto, PhD** • Protein Sciences Corporation — *Adventitious Virus Search in Sf9 Cells*
4:15 pm – 5:00 pm	**Elie Hanania, PhD** • MilliporeSigma *Assessment of the iCELLis Fixed-Bed Bioreactor for the Production of Viral Vectors: The Next Step to Scale-Up Adherent Cultures*	**Laura A. Struzyna** • University of Pennsylvania *Tissue Engineered Three-Dimensional 'Living Scaffolds' to Restore Nervous System Structure and Function*	**Gorben P. Pijlman, PhD** • Wageningen University *Virus-Like Particles (VLPs) and RNA Replicons as Next Generation Vaccines*
5:00 pm – 5:45 pm	**Hanna P. Lesch, PhD** • FinVector Vision Therapies OY — *Process Development and Large-Scale Clinical Production of Viral Vectors Using iCELLis® Technology*		**Pieter Neels, MD** • Vaccine-Advice BVBA *Registering a Novel, Innovative Medicinal Product in the EU: A Nightmare or Just a Learning Process?*
5:45 pm – 8:00 pm	**Reception in the Exhibit Area**		

Due to circumstances beyond the control of meeting organizers, this program is subject to change without notice.

ISBioTech 6th Spring Meeting (continued): TUESDAY • MARCH 8, 2016			
	Viral Vectors & Vaccines Rehearsal Hall	**Cellular Therapies** Classroom	**Baculovirus Expression Technology** Kreeger Theater
7:30 am – 8:30 am	**Breakfast in the Exhibit Area**		
8:30 am – 9:15 am	**David R. Knop, PhD** • Applied Genetic Technologies Corporation — *Toward Late Phase Clinical Manufacturing of AAV by Herpes-Assisted Vector Expansion (HAVE)*	**Ian M. Pope, PhD** • Brooks Life Science Systems *Practical, Quality, and Financial Perspectives of Repository Infrastructure Strategies*	**Peter Pushko, PhD** • Medigen, Inc. *Preparation of Quadrivalent Influenza Virus-Like Particles (VLPs) Using the Baculovirus Expression System*
9:15 am – 10:00 am	**María Mercedes Segura, PhD** • bluebird bio Inc. *Late-Stage Process Development for Lentiviral Vectors*	**Sébastien Sart** • École Polytechnique *High-Density 3D Cell Culture in an Integrated Microfluidic Platform*	**Ross Taylor, PhD** • Takeda Vaccines (Montana), Inc. — *Commercial-Scale Manufacturing of Norovirus Virus-Like Particles*
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:15 am	**Christine Le Bec, PhD** • Généthon *Assessment of AAV Vector Activity*	**Mercy Quagraine, PhD** • FDA CBER *Testing of Cellular Therapy Products*	**Cristina Costa Peixoto, PhD** • Instituto de Biologia Experimental e Tecnológica (iBET) *Improving and Monitoring an Influenza Virus-Like Particle (VLP) Downstream Process Using a Click Chemistry Strategy*
11:15 am – 12:00 noon	**Simon Simpkins, PhD** • Oxford BioMedica plc *Towards Commercial Supply of Lentiviral Vectors*	**Kelvin G.M. Brockbank, PhD** • Tissue Testing Technologies LLC — *Potential Applications of Natural Antifreeze Compounds in Cell Cryopreservation*	**Laura A. Palomares, ScD** • Universidad Nacional Autónoma de México — *Influence of the Cellular Environment During Baculovirus Infection*
12:00 noon – 1:30 pm	**Lentivirus Reference Material Working Group Meeting in the Rehearsal Hall**		
1:30 pm – 6:00 pm	**Free Afternoon with Recommended Activities**		
6:00 pm – 9:00 pm	**Rock the Casbah Banquet in the Molly Smith Study**		
WEDNESDAY • MARCH 9, 2016			
7:30 am – 8:30 am	**Breakfast in the Exhibit Area**		
8:30 am – 9:15 am	**Alexander N. Kotov, MD, PhD** • IDT Biologika Corporation — *Chimpanzee Adenoviral Vectors as an Advanced Technology Platform for Scalable Tuberculosis Vaccine Production*	**Michael Paglia** • bluebird bio Inc. *Demonstrating Comparability of Process Improvements for Autologous Gene Therapy Products*	**Michael Massare, PhD** • Novavax, Inc. *Protein Nanoparticle Vaccines: A New Platform for the Baculovirus-Insect Cell Expression System*
9:15 am – 10:00 am	**Bryan T. Butman, PhD** • GenVec, Inc. *A Commercializable Manufacturing System for GenVec's AdenoVerse™ Platform*	**Joseph A. Fraietta, PhD** • University of Pennsylvania — *Ibrutinib Enhances Chimeric Antigen Receptor T Cell Engraftment and Efficacy in Leukemia*	**Wian de Jongh, PhD** • ExpreS^{2}ion Biotechnologies *Development of Drosophila S2-Based Vaccine Production Processes*
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:15 am	**Nicole Faust, PhD** • Cevec Pharmaceuticals GmbH *CAP-GT, Novel Human Suspension Cell Lines for Scalable Production of Viral Vectors*	**Priya Baraniak, PhD** • RoosterBio Inc. *Why Stem Cell Manufacturing Matters: How Cell Therapy BioProcess Innovations are Accelerating the Tissue Engineering Revolution*	**Gary W. Blissard, PhD** • Boyce Thompson Institute for Plant Research — *A Global View of Viral and Host Gene Transcription Through the Infection Cycle: Early and Late Events in AcMNPV Infection of Trichoplusia ni Cells*
11:15 am – 12:00 noon	**Vladimir A. Slepushkin, MD, PhD** • Novartis Pharmaceuticals Corporation — *Process Development for Commercial Production of Lentiviral Vectors*	**Nicolas Taquet** • Gradalis, Inc. *Phase II/III Ovarian Tumor Tissue Processing to Prepare an Autologous Tumor Cell Vaccine*	**Jacek Lubelski, PhD** • uniQure N.V. *Use of BEVS Technology to Express Various Ratios of Three Adeno-Associated Virus Capsid Proteins*
12:00 noon – 1:30 pm	**Lunch in the Exhibit Area** (**Poster Session** from 1:00 pm – 1:30 pm)		
1:30 pm – 2:15 pm	**Andrew Worden** • Lentigen Technology Inc., a Miltenyi Biotec Company — *Towards a Commercial Process for the Manufacture of CAR T Cells*	**John M. Baust, PhD** • CPSI Biotech *New Technologies for Improved Handling of Cryopreserved Samples*	**Robin Levis, PhD** • FDA CBER *A Regulatory Perspective on Baculovirus Expression Systems*
2:15 pm – 3:00 pm	**Eric Gershenow** • Pall Life Sciences *Optimization of a Tangential Flow Filtration (TFF) Process Using Flat Sheet Cassettes for Concentration and Purification of Enveloped Vesicular Stomatitis Virus (VSV)*	**Ian K. McNiece, PhD** • MD Anderson Cancer Center — *Combination Cell Products for Regenerative Medicine*	**April Birch** • Kempbio, Inc. *Direct, Real-Time Quantification of Sf9-Derived Baculovirus Particles Employing Fluorescently-Tagged Antibodies*
3:00 pm – 3:30 pm	**Afternoon Break in the Exhibit Area** (**Exhibit Teardown** begins at 3:30 pm)		
3:30 pm – 4:15 pm	**Caroline I. Sellin, PhD** • Sanofi Pasteur SA *Fast-Track Lentiviral Vector Upstream Process Development*	**Terry J. Fry, MD** • National Cancer Institute *CAR T Cell Therapy for Pediatric Leukemia*	**Thera Mulvania, PhD** • Expression Systems, LLC *Development of an Insect Cell Medium for ^{15}N Labelling of Expressed Proteins*
4:15 pm – 5:00 pm	**Arifa S. Khan, PhD** • FDA CBER *Considerations for Use of New Technologies for Evaluation of Cell Substrates for Vaccines*	**Siddharth Gupta** • Lonza Walkersville, Inc. *Automation for Next-Generation Allogeneic Cell Therapy Manufacturing*	**Kari Airenne, PhD** • FinVector Vision Therapies OY *Baculovirus as a Vector in Ocular Gene Delivery*
5:00 pm	**Meeting Adjourns**		

All meals and events in the program are included with the registration fee.

REV 030916